ArticleMediterranean journal of rheumatology2025
Interstitial Lung Disease and Pulmonary Arterial Hypertension Screening Practices in Systemic Sclerosis: Survey Insights of Rheumatologists in the Middle East and North Africa Region.
Article in Mediterranean journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are significant causes of morbidity and mortality in systemic sclerosis (SSc). Our objective was to determine screening practices for ILD and PAH in patients with SSc among rheumatologists in the Middle East and North Africa (MENA) region. Methods: An online questionnaire was distributed to rheumatologists across the MENA region. Participants were asked to estimate the proportion of SSc patients in their practice, indicate whether they screen for ILD and PAH, and specify how often they utilise screening modalities, including chest X-ray (CXR), high-resolution CT (HRCT), pulmonary function tests (PFTs), echocardiograms (ECHO), and the use of the DETECT algorithm. Data were analysed using descriptive statistics, with p-values ≤0.05 regarded as statistically significant. Results: 394 respondents completed the questionnaire from 17 MENA countries. 389 (98.73%) reported screening for ILD, and 369 (93.65%) screened for PAH. 270 respondents performed screening at the time of SSc diagnosis (68.53%). Screening approaches for ILD included CXR (211, 53.55%), HRCT (321, 81.47%), and PFTs (299, 75.89%), while PAH screening included ECHO (346, 87.82%), and the DETECT algorithm (26.14%). Statistical differences were observed in the average number of SSc patients seen per year (p=0.0008), gender of respondents (p=0.02), current age (p=0.02), background training (p<0.00001), use of ECHO as PAH screening (p=0.01), and the DETECT algorithm (p=0.000017) between SSc experts and non-SSc experts. Conclusions: Our findings reflect real-world screening practices in SSc patients, emphasising discrepancies which could stem from variations in clinical training, resource availability, or institutional protocols across healthcare settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.